

PD98059

Chemical Properties

CAS No. : 167869-21-8


Formula: C₁₆H₁₃NO₃

Molecular Weight: 267.28

Keep away from direct sunlight

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	PD98059 is an MEK inhibitor that inhibits MEK1 and MEK2 (IC ₅₀ =2/50 μM) and is non-ATP-competitive. PD98059 is also antagonistic as a ligand for AHR. PD98059 inhibits autophagy.
Targets(IC ₅₀)	ERK,Aryl Hydrocarbon Receptor,MEK,Autophagy
In vitro	<p>METHODS: Human breast cancer cells MCF-7 and MDA-MB-231 were treated with PD98059 (1-50 μM) for 12-72 h. Cell viability was detected using MTT.</p> <p>RESULTS: PD98059 dose-dependently and time-dependently inhibited the enhancement of breast cancer tumor cells. [1]</p> <p>METHODS: Multidrug-resistant tumor cells SMMC7721/ADM and BEL7402/ADM were treated with PD98059 (2.5-20 μM) for 1 h, and the expression levels of target proteins were detected by Western Blot.</p> <p>RESULTS: PD98059 down-regulated pERK1/2 expression in cells in a dose-dependent manner. [2]</p>
In vivo	<p>METHODS: To test the effect on non-infectious shock, PD98059 (10 mg/kg) was administered intraperitoneally to CD mice with yeast polysaccharide-induced non-infectious shock.</p> <p>RESULTS: Treatment with PD98059 significantly reduced systemic toxicity, weight loss and mortality induced by yeast polysaccharide. [3]</p> <p>METHODS: To investigate the effects on experimental autoimmune encephalitis (EAE), PD98059 (5 mg/kg) was administered intraperitoneally once daily for two weeks to the SJL/J mouse model of EAE.</p> <p>RESULTS: PD98059 corrected immune dysfunction in EAE mice, which occurred concomitantly with the modulation of multiple signaling pathways. [4]</p>
Kinase Assay	c-Raf and MEK kinase were measured by their ability to activate MAPKK1 (or MAPKK2) in a 30-min coupled assay containing MAPKK1 (or MAPKK2) and its substrate p42 MAP kinase. One unit of c-Raf or MEK kinase activity was that amount which increased the activity of p42Graphic by 1 unit/min. MAPKK was assayed directly in the cell lysate by the activation of bacterially expressed p42Graphic. One unit of MAPKK was that amount which increased the activity of p42Graphic by 1 unit/min. The assays of c-Raf and MAPKK are quantitative and extremely sensitive and are detailed elsewhere. p42Graphic was assayed by its ability to phosphorylate myelin basic protein and MAPKAP kinase 1 α/β by the phosphorylation of a peptide related to the C terminus of ribosomal protein

Kinase Assay	S6 [Gly-245, Gly-246]S6-(218-249). One unit of p42Graphic or MAPKAP kinase-1 α/β was that amount which catalyzed the phosphorylation of 1 nmol of substrate peptide in 1 min. Protein kinase activities in immunoprecipitates were measured by adding the other assay components to the tubes containing the immunoprecipitated enzyme [1].
Cell Research	The MCF10A-Neo and MCF10A-NeoT lines were derived by transfection of the MCF10A cell line with the pHo6 plasmid and the pHo6 plasmid containing an Ha-ras oncogene derived from the human T24 bladder carcinoma cell line, and subsequent selection for resistance to G418. The transfected lines represent pooled survivors, as opposed to clonal lines. With the exception of the EGF content being increased from 10 to 20 ng/ml, the cells were cultured in supplemented Dulbecco's modified Eagle's medium/Ham's F-12 medium in a humidified atmosphere of 95% air/5% CO ₂ at 37°C. Subconfluent cultures were treated with varying concentrations of chemicals dissolved in DMSO (absolute volume of solvent < 0.1% of medium volume). Subconfluent cultures are treated with PD98059 (0-100 μ M). Viability of cells after treatment was assessed by ability to exclude trypan blue. Cultures earmarked for RNA isolation were washed twice with phosphate-buffered saline (2.7 mM KCl, 1.5 mM KH ₂ PO ₄ , 137mM NaCl, 8 mM Na ₂ HPO ₄ , pH 7.2) at harvesting and stored at 280°C [2].
Animal Research	Mice were randomized into 4 groups (n= 40 animals/group): (i) CAR + vehicle group. Mice were subjected to carrageenan-induced pleurisy and received the vehicle for PD98059 (10% dimethylsulfoxide (DMSO) (v/v) i.p. bolus 1 h after carrageenan administration(N=10); (ii) PD98059 group. Same as the CAR + vehicle group but were administered PD98059 (10 mg/kg, i.p. bolus) 1 h after carrageenan administration (N=10); (iii) Sham+saline group. Sham-treated group in which identical surgical procedures to the CAR group were performed, except that the saline was administered instead of carrageenan (n=10); (iv) Sham+ PD98059 group. Identical to Sham+saline group except for the administration of PD98059 (10 mg/kg i.p. bolus) 1h after carrageenan administration of saline (N=10). The doses of PD98059 (10 mg/kg) used here were based on previous in vivo studies that demonstrated regulation of the inflammation process [4].

Solubility Information

Solubility	Ethanol: 1.3 mg/mL (4.86 mM),Sonication is recommended. DMSO: 29.17 mg/mL (109.14 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 0.67 mg/mL (2.51 mM),Suspension. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.7414 mL	18.707 mL	37.4139 mL
5 mM	0.7483 mL	3.7414 mL	7.4828 mL
10 mM	0.3741 mL	1.8707 mL	3.7414 mL
50 mM	0.0748 mL	0.3741 mL	0.7483 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Zhao Y, et al. MEK inhibitor, PD98059, promotes breast cancer cell migration by inducing β -catenin nuclear accumulation. *Oncol Rep.* 2017 Nov;38(5):3055-3063.
- Xu X, Song L, Li Y, et al. Neurotrophin-3 promotes peripheral nerve regeneration by maintaining a repair state of Schwann cells after chronic denervation via the TrkC/ERK/c-Jun pathway. *Journal of Translational Medicine.* 2023, 21(1): 1-20.
- Chen M S, Tung Y W, Hu C L, et al. Three Lipid Emulsions Reduce Staphylococcus aureus-Stimulated Phagocytosis in Mouse RAW264. 7 Cells. *Microorganisms.* 2021, 9(12): 2479.
- Dong L, Gong J, Wang Y, et al. Chiral geometry regulates stem cell fate and activity[J]. *Biomaterials.* 2019: 119456.
- Chen M S, Lin W C, Yeh H T, et al. Propofol specifically reduces PMA-induced neutrophil extracellular trap formation through inhibition of p-ERK and HOCl. *Life Sciences.* 2019 Mar 15;221:178-186
- Li S, Deng G, Su J, et al. A novel all-trans retinoic acid derivative regulates cell cycle and differentiation of myelodysplastic syndrome cells by USO1. *European Journal of Pharmacology.* 2021: 174199.
- Liu Z, Yang J. Uncarboxylated osteocalcin promotes osteogenic differentiation of mouse bone marrow-derived mesenchymal stem cells by activating the Erk-Smad/ β -catenin signalling pathways. *Cell Biochemistry and Function.* 2019
- Chen M S, Yang K S, Lin W C, et al. Lipofundin mediates major inhibition of intravenous propofol on phorbol myristate acetate and Escherichia coli-induced neutrophil extracellular traps. *Molecular Biology Reports.* 2022: 1-13
- Yeh H T, Tsai Y S, Chen M S, et al. Flavopereirine induces cell cycle arrest and apoptosis via the AKT/p38 MAPK/ERK1/2 signaling pathway in human breast cancer cells. *European Journal of Pharmacology.* 2019, 863: 172658
- Zheng Y, Wang Y, Zhang X, et al. C19, a C-terminal peptide of CKLF1, decreases inflammation and proliferation of dermal capillaries in psoriasis. *Scientific Reports.* 2017, 7(1): 1-11
- Yang Z, Guo D, Zhao J, et al. Aggf1 Specifies Hemangioblasts at the Top of Regulatory Hierarchy via Npas4l and mTOR-S6K-Emp2-ERK Signaling. *Arteriosclerosis, Thrombosis, and Vascular Biology.* 2023
- Kong F, Liu H, Xu T, et al. RG108 attenuates acute kidney injury by inhibiting P38 MAPK/FOS and JNK/JUN pathways. *International Immunopharmacology.* 2024, 142: 113077.
- Guo K, Gao L, Li P, et al. Allopregnanolone relieves paclitaxel induced mechanical hypersensitivity via inhibiting spinal cord PGE2-EP2 mediated microglia-neuron signaling. *IBRO Neuroscience Reports.* 2025
- Zou X, Zeng M, Zheng Y, et al. Comparative Study of Hydroxytyrosol Acetate and Hydroxytyrosol in Activating Phase II Enzymes. *Antioxidants.* 2023, 12(10): 1834.
- Chen S, et al. Reversing multidrug resistance in hepatocellular carcinoma cells by inhibiting extracellular signal-regulated kinase/mitogen-activated protein kinase signaling pathway activity. *Oncol Lett.* 2014 Nov;8(5):2333-2339.
- Gao K, Si M, Qin X, et al. Transcription factor XBP1s promotes endometritis-induced epithelial-mesenchymal transition by targeting MAP3K2, a key gene in the MAPK/ERK pathway. *Cell Communication and Signaling.* 2025, 23 (1): 72.
- Urade R, Chang W T, Ko C C, et al. A fluorene derivative inhibits human hepatocellular carcinoma cells by ROS-mediated apoptosis, anoikis and autophagy. *Life Sciences.* 2023: 121835.
- Di Paola R, et al. PD98059, a specific MAP kinase inhibitor, attenuates multiple organ dysfunction syndrome/failure (MODS) induced by zymosan in mice. *Pharmacol Res.* 2010 Feb;61(2):175-87.
- Liu Y, Yuan C, Zhou M, et al. Co-cultured Bone-marrow Derived and Tendon Stem Cells: Novel Seed Cells for Bone Regeneration. *Open Life Sciences.* 2019, 14(1): 568-575
- Ahmad SF, et al. MAP kinase inhibitor PD98059 regulates Th1, Th9, Th17, and natural T regulatory cells in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. *Eur J Pharmacol.* 2023 Nov 15; 959:176086.
- Yeh H T, Tsai Y S, Chen M S, et al. Flavopereirine induces cell cycle arrest and apoptosis via the AKT/p38 MAPK/ERK1/2 signaling pathway in human breast cancer cells[J]. *European Journal of Pharmacology.* 2019: 172658.
- Chen M S, Yeh H T, Li Y Z, et al. Flavopereirine Inhibits Autophagy via the AKT/p38 MAPK Signaling Pathway in MDA-MB-231 Cells. *International Journal of Molecular Sciences.* 2020, 21(15): 5362

- Chen M S, Lin W C, Yeh H T, et al. Propofol specifically reduces PMA-induced neutrophil extracellular trap formation through inhibition of p-ERK and HOCl[J]. *Life sciences*. 2019 Mar 15;221:178-186.
- Li P, Lin Q, Sun S, et al. Inhibition of cannabinoid receptor type 1 sensitizes triple-negative breast cancer cells to ferroptosis via regulating fatty acid metabolism. *Cell Death & Disease*. 2022, 13(9): 1-15.
- Dong L, Gong J, Wang Y, et al. Chiral geometry regulates stem cell fate and activity. *Biomaterials*. 2019: 119456.
- Hu, Qihui, Hengjun Du, Gaoxing Ma, Fei Pei, Ning Ma, Biao Yuan, Paul A. Nakata, and Wenjian Yang. Purification, identification and functional characterization of an immunomodulatory protein from *Pleurotus eryngii* [J]. *Food Funct*. 2018 Jul 17;9(7):3764-3775.
- Chen M S, Yeh H T, Li Y Z, et al. Flavopereirine Inhibits Autophagy via the AKT/p38 MAPK Signaling Pathway in MDA-MB-231 Cells[J]. *International Journal of Molecular Sciences*. 2020, 21(15): 5362.
- Su J W, Li S F, Tao J J, et al. Estrogen protects against acidosis-mediated articular chondrocyte injury by promoting ASIC1a protein degradation. *European Journal of Pharmacology*. 2021: 174381.
- Hu Q, Du H, Ma G, et al. Purification, identification and functional characterization of an immunomodulatory protein from *Pleurotus eryngii*. *Food & Function*. 2018, 9(7): 3764-3775
- Zheng Y, Wang Y, Zhang X, et al. C19, a C-terminal peptide of CKLF1, decreases inflammation and proliferation of dermal capillaries in psoriasis[J]. *Scientific Reports*. 2017 Oct 24;7(1):13890.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481